Latest Breaking News On - About actinium pharmaceuticals - Page 1 : comparemela.com

Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today.

United statesHannah choeAstellas pharmaAvinash desaiAmerican society of hematology meeting expositionProfessor of medicine at ohio state universityPrnewswire actinium pharmaceuticals incOncology lg chem life sciencesActimaba national cancer instituteExchange commissionActinium pharmaceuticals incOverall survivalAnnual american societyHematology meetingComplete remissionAssistant professor

Actinium Pharma (ATNM) Highlights First-In-Class HER3 Targeted Radiotherapy Data

Actinium Pharma (ATNM) Highlights First-In-Class HER3 Targeted Radiotherapy Data
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesHans vitzthumDevelopment agreementAstellas pharma incEpicentrx incActinium pharmaceuticals incOncology incMemorial sloan kettering cancer centerAmerican association for cancer researchNational cancer instituteLifesci advisorsAmerican associationCancer researchAbout actinium pharmaceuticalsElderly relapsedRefractory acute myeloid leukemia

Actinium Pharmaceuticals Reports 2022 Financial Results and Highlights Recent and Upcoming Clinical Data and Milestones

- Announced positive results from the pivotal Phase 3 SIERRA trial of Iomab-B in r/r AML patients ages 55+; achieved primary endpoint of dCR with high.

United statesSandesh sethHans vitzthumAmerican society of hematologyOncology groupEpicentrx incNational institutes of healthLifesci advisorsColumbia universityActinium pharmaceuticals incDevelopment agreementExchange commissionEastern cooperative oncology groupNational cancer instituteExperimental therapeutics clinical trials networkLg chem company

Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia

- Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical.

United statesMadhuri vusirikalaCaroline yarbroughSandesh sethHans vitzthumVenetoclax bclSergio giraltAvinash desaiLifesci advisorsActinium pharmaceuticals incDivision of hematologic malignanciesService at memorial sloan kettering cancer centerClinical developmentComplete remissionActinium pharmaceuticalsInvestor conference call

Actinium Appoints Seasoned Leader Caroline Yarbrough as Chief Commercial Officer to Spearhead Iomab-B Commercialization

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today.

Caroline yarbroughBristol myers squibbSandesh sethHans vitzthumLifesci advisorsGoizueta business school at emory universityMerck coUniversity of delawareNijenrode universityInternational businessPeter white undergraduate research fellowshipActinium pharmaceuticals incPrnewswire actinium pharmaceuticals incPortfolio general managerGlaxo smithklineChief commercial